Dr. Jun Shimazaki, Professor Emeritus of Tokyo Dental College, Appointed as Scientific Advisor to Cellusion


Cellusion Inc. (Head Office: Tokyo; CEO: Shin Hatou; hereinafter referred to as “Cellusion”), which has “Regenerating Human Potential” as its mission and aims to meet the demands of corneal transplant patients worldwide with its unique technique that efficiently produces corneal endothelial replacement cells from iPS cells, is pleased to announce that Jun Shimazaki, M.D., Ph.D., has been appointed as its scientific advisor.

Under our new structure, Cellusion will further accelerate its business development toward the social implementation of our lead program: iPS cell-derived corneal endothelial cell substitute (hereinafter referred to as “CLS001”).

Scientific Advisor, Jun Shimazaki, M.D., Ph.D. (newly appointed)

[About Jun Shimazaki, M.D., Ph.D.]
After graduating from Keio University and furthering his studies at Harvard University, Dr. Shimazaki worked at the Department of Ophthalmology of Tokyo Dental College Ichikawa General Hospital from 1992, and was appointed as its professor of ophthalmology in 2006. Dr. Shimazaki has been the Director of Akasaka Shimazaki Eye Clinic from 2023, and is also serving as the Councilor of the Japanese Ophthalmological Society and Councilor of the Japan Cornea Society.
Having performed more than 2,000 corneal transplants, Dr. Shimazaki is known as a specialist in the diagnosis and treatment of corneal diseases, corneal regenerative medicine, and treatment of severe ocular surface diseases, and he is also actively engaged in disease awareness activities and activities of the Cornea Transplant Support Community.

[About Cellusion]
Cellusion is a regenerative medicine startup originating from the Department of Ophthalmology, Keio University School of Medicine, with “Regenerating Human Potential” as its mission and “More Freedom and More Smiles to the World” as its vision. Based on patented technology such as its proprietary technique of efficiently producing corneal endothelial substitute cell from iPS cells, Cellusion is promoting R&D aimed at meeting medical needs from the perspective of “patient centricity” by leveraging cutting-edge regenerative medicine technology, including the lead program CLS001 that aims to meet the global corneal transplant demands.

Company: Cellusion Inc.
CEO: Shin Hatou, M.D., Ph.D.
Headquarters: 8-6 Nihonbashi-Kobuna, Chuo, Tokyo 103-0024, JAPAN
Founded: January 2015

For further information: please ask us through the contact form on our website.

Back to the List